Luca Malorni

Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial

Angelo Di Leo, Guy Jérusalem, Luboš Petruželka et al. · JNCI Journal of the National Cancer Institute · 2013 · 328 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up

Luca Malorni, Priya B. Shetty, Carmine De Angelis et al. · Breast Cancer Research and Treatment · 2012 · 266 citations

Medicine, Cancer Biology, Oncology +16

A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer

Luca Malorni, Silvano Piazza, Yari Ciani et al. · Oncotarget · 2016 · 170 citations · Full text

Medicine, Bioinformatics, Oncology +17

Heterogeneity of <i>PIK3CA</i> mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

Marta Pestrin, Francesca Salvianti, Francesca Galardi et al. · Molecular Oncology · 2014 · 166 citations · Full text

Medicine, Genetics, Oncology +16

Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts

Chad J. Creighton, Suleiman Massarweh, Shixia Huang et al. · Cancer Research · 2008 · 138 citations · Full text

Medicine, Oncology, Pharmacology +17